检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]青岛大学医学院附属青岛市市立医院耳鼻咽喉科,山东青岛266011
出 处:《齐鲁医学杂志》2009年第2期101-103,共3页Medical Journal of Qilu
摘 要:目的探讨Survivin和eIF4E在喉鳞癌组织中的表达及其相互关系。方法应用免疫组化法测定40例喉鳞癌组织标本及20例声带息肉组织中Survivin与eIF4E的表达,并进行比较。结果Survivin在喉鳞癌标本中的阳性表达率为65%,而在声带息肉组织中的阳性表达率为25%,二者比较差异有显著性(χ2=12.19,P<0.05)。Survivin的表达与喉鳞癌临床分期、分化程度有明显的相关性(χ2=8.993、7.238,P<0.05),而与淋巴结转移无相关性(χ2=1.134,P>0.05)。eIF4E在喉鳞癌和声带息肉组织中的阳性表达率分别为97.5%和65.0%,二者比较差异有显著性(χ2=8.54,P<0.05),其与临床分期、分化程度、淋巴结转移情况无明显相关性(χ2=0.054~2.477,P>0.05)。Survivin和eIF4E在喉鳞癌组织中的表达无相关性(r=0.11,P>0.05)。结论Survivin与eIF4E在喉鳞癌组织中的过度表达与喉鳞癌的发生有关,但两者在喉癌组织中表达的相关性还有待进一步研究。Objective To investigate the expressions of Survivin and eIF4E in laryngeal squamous cell carcinoma (LSCC) and their correlation with this disease. Methods Expressions of Survivin and eIF4E in specimens of 40 LSCC and 20 cases with polyp of vocal cord (PVC) were detected via immunohistochemical technique. Results The positive rates of Snrvivin were 65% in LSCC and 25 % in PVC, the difference was significant (χ^2 = 12.19, P〈0.05). Survivin expression was correlated with the clinical stage and the tumor differentiation (χ^2 =8. 993,7. 238;P〈0.05), but not with lymph-node metastasis (χ^2 =1. 134,P〉0.05). The positive rates of eIF4E in LSCC and PVC were 97.50% and 65.0 %, respectively, the difference was significant (χ^2 = 8.54, P〈 0.05). The expression eIF4E in LSCC was not correlated with the clinical stage, tumor differentiation and lymph-node metastasis (χ^2 = 20. 054-2. 477, P〉0.05). There was no correlation between the expressions of Survivin and eIF4E LSCC (r= 0.11, P〉 0.05). Conclusion Overexpressions of Survivin and eIF4E are associated with the pathogenesis of LSCC, but the relationship between the two expressions in the disease needs further study.
关 键 词:喉肿瘤 Survivin蛋白质 eIF4E蛋白质 免疫组织化学
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.117.229.13